MXCT — MaxCyte Income Statement
0.000.00%
Last trade - 00:00
- £332.48m
- £196.44m
- $41.29m
- 18
- 12
- 83
- 28
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 21.6 | 26.2 | 33.9 | 44.3 | 41.3 |
Cost of Revenue | |||||
Gross Profit | 19.1 | 23.4 | 30.2 | 39.2 | 36.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 34 | 37.2 | 52.1 | 71.6 | 89.6 |
Operating Profit | -12.4 | -11.1 | -18.2 | -27.4 | -48.3 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -12.9 | -11.8 | -19.1 | -23.6 | -37.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.9 | -11.8 | -19.1 | -23.6 | -37.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.9 | -11.8 | -19.1 | -23.6 | -37.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.9 | -11.8 | -19.1 | -23.6 | -37.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.229 | -0.17 | -0.211 | -0.232 | -0.367 |